BMDM delivery of therapeutic nanoparticles enhances the efficacy of radiation therapy.

<p>(A) Tumor growth curve of TRAMP-C1 tumors growing subcutaneously in the thigh following various combination treatments. IR: 25 Gy of radiation was given when tumor diameter is around 5 mm. PBS, Dox, PAAC-Dox or BMDMs-PAAC-Dox was given intravenously at 1, 4, and 7 days after radiation treatment. The data represent the average of three to five mice from each group of one representative data set of 3 independent repeated experiments. (B) Comparison of tumor volume at the end of experiments. Bar: SE. **: P<0.01; ***: P <0.005; n.s.: P >0.05 by one way ANOVA test. (C) and (D) Representative fluorescent imaging of tumor tissues obtained from one day after the last administration of PAAC-Dox. (E) and (F) Representative fluorescent imaging of tumor tissues obtained from one day after the last administration of BMDM-PAAC-Dox. scale bar = 50 um. Comparison of DOX fluorescent intensity within PIMO negative versus PIMO positive region after one injection (G) or three injections (H) of PAAC-Dox versus BMDMs-PAAC-Dox between tumor with (IR) and without (w/o IR) 25 Gy of irradiation. The data represent the average Dox fluorescent intensity within PIMO- or PIMO+ region of 5 randomly selected fields of each tumor from 3 tumor tissues was analyzed by Image Pro 6 under same exposure time of 40X objective lens imaging. Bar: SE. ***: P <0.005; **: P<0.01; *: P<0.05 by one way ANOVA test.